Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Ingram

Psychiatry Bay City, MI Medical Doctor

NPI 1295767283 CMS profile 330449

690 S Trumbull, Bay City, MI 48708

Open in the dashboard

General payments

$255,285

491 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Ingram of Bay City, MI is reported in the CMS Open Payments database as having received $255,285 across 491 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36,483 68
2024 General $44,578 59
2023 General $17,684 52
2022 General $44,473 82
2021 General $28,846 44
2020 General $26,805 48
2019 General $56,416 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Ingram
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Michael Ingram were reported at $36,483. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Michael Ingram Psychiatry median Middle half National median
2019 $56,416 $184 $59–$605 $163
2020 $26,805 $119 $36–$372 $114
2021 $28,846 $143 $43–$576 $132
2022 $44,473 $153 $50–$590 $149
2023 $17,684 $170 $56–$651 $160
2024 $44,578 $179 $57–$673 $164
2025 $36,483 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $91,893 133 payments
  2. Alkermes, Inc. $73,024 103 payments
  3. Otsuka America Pharmaceutical, Inc. $33,941 80 payments
  4. ITI, Inc. $25,642 36 payments
  5. Teva Pharmaceuticals USA, Inc. $21,332 37 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $7,539 12 payments
  7. Neurocrine Biosciences, Inc. $359 23 payments
  8. Validus Pharmaceuticals LLC $346 3 payments
  9. Lundbeck LLC $255 15 payments
  10. AbbVie, Inc. $206 10 payments
  11. Other $747 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $191,827 98 payments
  2. Travel and Lodging $29,284 74 payments
  3. Consulting Fee $21,640 8 payments
  4. Food and Beverage $12,495 307 payments
  5. Education $38 4 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $82,131 104 payments
  2. INVEGA TRINZA $81,171 93 payments
  3. ARISTADA Cns $50,862 74 payments
  4. ARISTADA Cns $50,862 74 payments
  5. ARISTADA Cns $50,726 68 payments
  6. ARISTADA Cns $50,726 68 payments
  7. ARISTADA INITIO $41,417 65 payments
  8. LYBALVI Cns $31,694 41 payments
  9. LYBALVI Cns $22,249 32 payments
  10. LYBALVI Cns $22,113 26 payments
  11. Other $126,586 348 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,760

Median for Psychiatry: 574

Drug cost

$923,746

Median for Psychiatry: $27,624

Branded share of claims

27.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 52 $321,555
Ingrezza Valbenazine Tosylate Brand 14 $156,964
Austedo Xr Deutetrabenazine Brand 24 $114,964
Vraylar Cariprazine Hcl Brand 58 $86,789
Rexulti Brexpiprazole Brand 34 $72,556
Trintellix Vortioxetine Hydrobromide Brand 46 $38,577
Auvelity Dextromethorphan Hbr/Bupropion Brand 18 $26,036
Emsam Selegiline Brand 11 $22,965
Spravato Esketamine Hcl Brand 11 $18,155
Paliperidone Er Paliperidone Brand 45 $7,700

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$1,595

Medicare's payments for the services billed

Medicare patients

14

Average age 63

Services billed

40

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
COPD 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $19,139
$19,139 — —
INVEGA TRINZA
  • Janssen Pharmaceuticals, Inc $18,499
$18,499 — —
ABILIFY ASIMTUFII
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $5,184
$5,184 — —
ABILIFY MAINTENA
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $1,203
  • Otsuka America Pharmaceutical, Inc. $14
$1,217 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $116
$116 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

491 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record